QuidelOrtho Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

The restricted stock units vest over three years, subject to each employee remaining employed through the applicable vesting dates.

Rhea-AI Summary

QuidelOrtho (QDEL) granted equity awards covering 50,323 common shares to two newly hired, non-executive employees as employment inducements.

The awards consist of restricted stock units (RSUs), granted on October 15, 2026, under the 2026 Inducement Plan. They vest in equal annual installments on the first three anniversaries of the grant date, subject to continued employment through each vesting date. The board's Compensation Committee approved the grants in accordance with Nasdaq Listing Rule 5635(c)(4).

Positive

• None.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.RSUs covering 50,323 common shares granted to two new employees represent potential shareholder dilution.

Key Figures

Aggregate RSU grant: 50,323 shares Recipients: 2 employees Vesting schedule: 3 equal annual installments

Aggregate RSU grant

50,323 shares

Granted to two newly hired non-executive employees

Recipients

2 employees

Newly hired, non-executive employees

Vesting schedule

3 equal annual installments

On the first three grant-date anniversaries, subject to continued employment

Key Terms

restricted stock units, nasdaq listing rule 5635(c)(4)

2 terms

restricted stock units financial

"The Inducement Grants consist of restricted stock units ("RSUs")"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"as an inducement material to each employee's entering into employment"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Oct. 15, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a leading global provider of diagnostic solutions, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of equity awards to two newly hired, non-executive employees (the "Inducement Grants"). The Inducement Grants were granted pursuant to the Company's 2026 Inducement Plan and as an inducement material to each employee's entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2026 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of QuidelOrtho, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with QuidelOrtho, pursuant to Nasdaq Listing Rule 5635(c)(4).

The Inducement Grants consist of restricted stock units ("RSUs") with respect to an aggregate of 50,323 shares of the Company's common stock. The RSUs were granted with a grant date of October 15, 2026, and will vest in equal annual installments on the first three anniversaries of the grant date, subject to the employee's continued employment with the Company through each applicable vesting date. The RSUs are subject to the terms and conditions of the 2026 Inducement Plan and the terms and conditions of a RSU award agreement covering each Inducement Grant.

QuidelOrtho is dedicated to advancing diagnostics to power a healthier future. For more information, please visit quidelortho.com and follow QuidelOrtho on LinkedIn, Facebook and X.

About QuidelOrtho Corporation
With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, dedicated to advancing fast, accurate and reliable results that help improve patient outcomes – from the point of care to hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.

Investor Contact:
Sanjeev Sharma
Vice President, Investor Relations
IR@QuidelOrtho.com

Media Contact:
Stephanie Kleewein
Senior Corporate Communication and PR Manager
media@QuidelOrtho.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/quidelortho-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302910665.html

SOURCE QuidelOrtho Corporation

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares do QuidelOrtho's October 2026 inducement grants cover?

The inducement grants cover 50,323 common shares through restricted stock units awarded to two newly hired, non-executive employees.

When do QuidelOrtho's October 2026 inducement RSUs vest?

The RSUs vest in equal annual installments on the first three anniversaries of October 15, 2026. Each installment requires the employee to remain employed through the applicable vesting date.